QY Research Inc. (Global Market Report Research Publisher) announces the release of 2025 latest report “Small Incision Lenticule Extraction Pro Equipment- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031”. Based on current situation and impact historical analysis (2020-2024) and forecast calculations (2025-2031), this report provides a comprehensive analysis of the global Small Incision Lenticule Extraction Pro Equipment market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Small Incision Lenticule Extraction Pro Equipment was estimated to be worth US$ 25.65 million in 2024 and is forecast to a readjusted size of US$ 101 million by 2031 with a CAGR of 20.8% during the forecast period 2025-2031.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5055281/small-incision-lenticule-extraction-pro-equipment
Small Incision Lenticule Extraction Pro Equipment Market Summary
The Small Incision Lenticule Extraction Pro (often referred to as SMILE Pro) equipment market reflects the evolution of femtosecond laser platforms specifically designed to optimize refractive surgery. Unlike the first generation of SMILE equipment, SMILE Pro devices focus on higher laser pulse frequencies, faster treatment times, improved docking systems, and integrated digital workflow features, which collectively enhance surgeon efficiency and patient comfort. This technological progression has reshaped the market from a niche innovation into a more mainstream solution in ophthalmology. The demand is driven not only by the clinical benefits of the SMILE technique itself—such as flapless correction, reduced risk of post-operative dry eye, and superior corneal biomechanical preservation—but also by the operational advantages that “Pro” versions bring to busy surgical centers where throughput and patient satisfaction are crucial.
Market structure in SMILE Pro equipment remains relatively consolidated. The core technology requires advanced femtosecond laser engineering, precise optics, and robust software integration, which only a small number of ophthalmic device manufacturers can deliver. These high entry barriers mean that early movers with established intellectual property, service networks, and surgeon training programs retain a dominant role. Clinics that already own first-generation SMILE equipment are strong candidates for upgrades, since the Pro versions offer shorter procedure times—often cutting surgery duration nearly in half—and thus improve clinical workflow and patient turnaround. This upgrade cycle forms a central pillar of current market growth.
According to the new market research report “Global Small Incision Lenticule Extraction Pro Equipment Market Report 2024-2031″, published by QYResearch, the global Small Incision Lenticule Extraction Pro Equipment market size is projected to grow from USD 25.65 million in 2024 to USD 101 million by 2031, at a CAGR of 20.7% during the forecast period.
This report profiles key players of Small Incision Lenticule Extraction Pro Equipment such as ZEIS, Ziemer, etc.
In 2024, the global top two Small Incision Lenticule Extraction Pro Equipment players account for 92% of market share in terms of revenue.
The evolution of refractive surgery has been marked by continuous innovations aimed at improving safety, patient comfort, and clinical outcomes. Among the most notable advancements is Small Incision Lenticule Extraction (SMILE), a minimally invasive laser vision correction procedure that eliminates the need for a corneal flap, as in LASIK. The latest stage of this innovation is known as SMILE Pro, an enhanced form of the original SMILE procedure that leverages improvements in femtosecond laser design, surgical workflow, and precision engineering. Two leading players, Carl Zeiss Meditec (ZEISS) and Ziemer Ophthalmic Systems (Ziemer), have contributed significantly to advancing SMILE Pro equipment, each following distinct approaches rooted in their technological strengths and strategic vision.
ZEISS has been the clear pioneer of SMILE technology, and its transition into SMILE Pro reflects its long-term commitment to minimally invasive refractive surgery. ZEISS introduced the original SMILE technique with its VisuMax femtosecond laser platform, which became the foundation for global clinical adoption. Recognizing the need to address surgeon workflow efficiency and enhance patient outcomes, ZEISS developed the VisuMax 800, a next-generation femtosecond laser system optimized for SMILE Pro procedures. Compared to its predecessor, the VisuMax 800 incorporates higher pulse frequency, improved laser delivery optics, and faster lenticule creation times, which significantly reduce procedure duration. These advancements not only increase surgeon confidence but also improve patient comfort by minimizing the time spent under suction. Furthermore, the system offers refined incision planning, better lenticule centration, and expanded treatment options, making SMILE Pro a versatile upgrade to the original technology.
Another critical aspect of ZEISS’s development is its emphasis on integrated digital workflows. The VisuMax 800 can be combined with ZEISS’s diagnostic and planning solutions, such as the ZEISS Refractive Workplace and corneal analysis platforms, ensuring smooth data transfer and treatment customization. This integration enhances surgical precision, reduces manual errors, and saves clinical time. ZEISS has also invested heavily in surgeon training programs, recognizing that even advanced equipment requires skilled hands to deliver optimal results. By combining hardware innovation with software integration and training infrastructure, ZEISS has positioned SMILE Pro not merely as a device, but as a comprehensive refractive surgery solution.
In parallel, Ziemer Ophthalmic Systems, a Swiss company known for its FEMTO LDV femtosecond laser series, has been carving its role in SMILE Pro development by emphasizing flexibility, compact system design, and high laser frequency technology. Unlike ZEISS, which has focused on establishing SMILE as a global standard, Ziemer’s approach is centered on expanding the potential applications of femtosecond lasers, including lenticule extraction procedures. The FEMTO LDV Z8, Ziemer’s flagship platform, is particularly notable for its low-energy, high-frequency laser architecture, which creates extremely smooth corneal cuts with minimal collateral tissue impact. This design is advantageous for lenticule creation, where precision and smoothness are critical for ease of extraction and postoperative recovery.
Ziemer’s development strategy for SMILE Pro emphasizes versatility and accessibility. The Z8 system is portable, modular, and designed to handle a broad range of anterior segment surgeries beyond refractive correction, such as keratoplasty and cataract procedures. This multifunctional approach allows smaller clinics to invest in a single platform that can serve multiple purposes, making it cost-effective compared to single-use systems. In terms of SMILE Pro procedures, Ziemer continues to collaborate with research institutions and surgeons to refine lenticule extraction techniques, aiming to improve incision customization and expand the treatable range of refractive errors.
While ZEISS holds the advantage of having pioneered SMILE and established a large clinical footprint, Ziemer contributes to the competitive diversification of SMILE Pro technology. Its innovations in compact design, modular flexibility, and laser pulse engineering push the boundaries of what femtosecond systems can achieve in minimally invasive refractive surgery. This dynamic ensures that the industry does not remain monopolized and that surgeons have alternatives suited to their practice needs.
The development paths of ZEISS and Ziemer highlight two complementary strategies shaping the future of SMILE Pro. ZEISS represents the global leader with a focus on technological refinement, workflow integration, and large-scale clinical adoption, while Ziemer embodies the agile innovator, prioritizing flexibility, cost-effectiveness, and technological experimentation. Together, these companies ensure that SMILE Pro evolves as both a standardized and adaptable solution for refractive correction.
In conclusion, the field of SMILE Pro equipment stands at the intersection of cutting-edge femtosecond laser engineering and the growing demand for minimally invasive vision correction. ZEISS and Ziemer, through their distinct but converging contributions, are shaping this future by balancing precision, efficiency, and accessibility. As patient demand for quick recovery, biomechanical safety, and long-lasting outcomes continues to rise, the innovations of these two companies will remain central to the ongoing evolution and global adoption of SMILE Pro.
Survey shows：
In the first half of 2025, Aier Eye Hospital reported an 11.14% year-on-year increase in revenue from its refractive surgery segment. A significant driver of this growth has been the widespread patient acceptance and accelerated clinical adoption of new procedures such as Total Refractive Solution (TRS) by Alcon, SMILE 4.0, and SMILE pro. These advanced techniques have contributed to the continuous optimization of the refractive service mix and a rise in the average procedure price. Similarly, Huaxia Eye Hospital achieved a 13.75% year-on-year growth in refractive revenue, partly attributable to its timely introduction and active promotion of advanced techniques like ZEISS’s SMILE pro, SMILE 4.0, and Alcon’s TRS. This strategic focus on upgrading its portfolio of refractive services has effectively enhanced the value and composition of its surgical offerings.
Both He Eye Specialist Hospital and Bright Eye Hospital also recorded modest growth in their refractive surgery segments. Their financial reports highlighted that the introduction of the latest-generation all-femtosecond equipment and the upgrading of refractive surgical techniques have enhanced their market competitiveness.
In the field of cataract treatment, the impact of the intraocular lens (IOL) volume-based procurement policy on ophthalmic medical institutions has been evident, with most experiencing declines in both revenue and gross margin. Similarly, accelerating technological iteration and upgrading surgical techniques have become critical measures to “rescue” cataract programs. For instance, the introduction of new-generation femtosecond laser systems for cataract surgery and the promotion of FLACS (femtosecond laser-assisted cataract surgery) have emerged as key strategies for institutions to mitigate declining revenue in this segment.
The proactive adoption and promotion of new equipment and surgical techniques by healthcare institutions have directly driven upstream equipment sales. Taking ZEISS’s all-femtosecond portfolio as an example: although its previous-generation systems and earlier SMILE 3.0 and SMILE 4.0 procedures still hold significant market share, the latest VISUMAX 800 model has been enthusiastically embraced by both institutions and patients.
According to data released by Zeiss, after its launch, the VISUMAX 800 was officially installed in hospitals in May 2025. In just three months by the end of August, its installations had covered 63 medical institutions across China. Additionally, the number of SMILE pro procedures performed using the VISUMAX 800 exceeded 20,000 within the same three-month period. Liu Yonghua, Head of Zeiss Group China, stated that a decade ago, it took two and a half years to reach 10,000 all-femtosecond (SMILE) procedures. Today, however, the number of SMILE pro procedures has surpassed 20,000 in just three months—representing nearly a 10-fold increase in speed.
In summary, within the fields of refractive and cataract surgery, the trend of high-end equipment—represented by femtosecond lasers—driving revenue growth on the service side is becoming increasingly evident. This not only reflects the structural shift in the sources of revenue and profit for ophthalmic institutions but also underscores the strong patient demand for new technologies and advanced surgical procedures.
Market development also faces challenges：
The introduction of Small Incision Lenticule Extraction Pro (SMILE Pro) represents a significant step forward in refractive surgery technology. Building on the original SMILE procedure, SMILE Pro delivers faster treatment times, improved surgical precision, and enhanced patient comfort through advanced femtosecond laser platforms. Despite these advantages, the development and adoption of SMILE Pro equipment face a range of obstacles that limit the speed and breadth of market growth. These challenges stem from economic, regulatory, technological, clinical, and market-related factors, which together shape the trajectory of this highly specialized industry.
A primary barrier is the high capital investment required for SMILE Pro equipment. Devices such as ZEISS’s VisuMax 800 or Ziemer’s FEMTO LDV Z8 represent state-of-the-art technology, but they are priced at levels that many smaller clinics or regional hospitals find prohibitive. Beyond the purchase price, there are ongoing costs related to maintenance, consumables, and licensing fees. This creates a high financial entry threshold that discourages widespread adoption, particularly in emerging economies where the burden of upfront investment is difficult to recover given limited patient demand for premium refractive surgery procedures.
Another hindrance is the restricted competitive landscape. ZEISS, as the pioneer and current leader in SMILE Pro technology, has established a dominant market position. While Ziemer and other companies are contributing innovations, the market remains relatively concentrated, limiting competition and keeping prices high. This monopoly-like environment slows diffusion of the technology, as clinics have fewer alternatives in terms of pricing, system features, or flexible financing models. Without a broader base of manufacturers, the growth of the industry is naturally restrained.
Regulatory hurdles are also a critical limiting factor. While SMILE and SMILE Pro have gained regulatory approval in several regions, the approval process in major markets such as the United States is time-consuming and resource-intensive. Regulatory bodies demand extensive clinical evidence on safety, efficacy, and long-term stability, which delays the entry of newer systems and restricts market availability. Furthermore, differences in regulatory standards across countries mean that while a system may be widely used in Europe or Asia, its adoption in North America could be delayed for years, preventing the global harmonization of SMILE Pro as a standard procedure.
From a clinical perspective, the learning curve for surgeons remains an obstacle. Even though SMILE Pro shortens procedure times and improves efficiency compared to earlier versions, it still requires precise surgical technique, especially in lenticule dissection and extraction. Surgeons trained primarily in LASIK may hesitate to invest the time and resources necessary to retrain on SMILE Pro systems, particularly when LASIK continues to generate reliable results and strong patient demand. Until training programs and case support become more widespread, this barrier will continue to limit adoption.
Patient awareness and demand represent another challenge. Although SMILE Pro offers biomechanical stability, faster healing, and reduced dry eye risk, many patients remain unaware of its advantages compared to LASIK. Decades of LASIK marketing have entrenched it as the “go-to” refractive surgery, making it difficult for newer technologies to break through. Without strong educational campaigns and patient outreach, demand for SMILE Pro remains concentrated in high-income urban markets, leaving large segments of the global population unserved.
In addition, limited treatment indications continue to hinder development. While SMILE Pro has expanded its scope compared to original SMILE, its primary strength remains in correcting myopia and astigmatism. Broader refractive errors, such as hyperopia and presbyopia, are not yet fully addressed by SMILE Pro technology. This limitation restricts its clinical applicability compared to LASIK, which is more versatile in treating a wide range of conditions. Until research and technology expand the indication range, SMILE Pro will remain a niche option rather than a universal refractive correction solution.
Another factor lies in technological dependence on proprietary systems. ZEISS and Ziemer rely on highly specialized hardware and software architectures, which lock users into proprietary ecosystems. This lack of interoperability limits surgeon flexibility and increases dependency on a single vendor for upgrades, service, and workflow integration. Such rigidity discourages some clinics from adopting the equipment, especially if they already operate established LASIK platforms that integrate seamlessly with their diagnostic and planning tools.
Finally, the industry faces competition from alternative solutions. New generations of implantable collamer lenses (ICLs), phakic intraocular lenses, and advanced multifocal intraocular lenses for presbyopia correction provide strong alternatives to SMILE Pro. These technologies offer different advantages, such as reversibility, wider indications, or immediate outcomes without the need for corneal tissue removal. The presence of strong competitors in the refractive surgery market dilutes the momentum of SMILE Pro adoption, especially in regions where affordability and accessibility drive patient decisions.
In summary, the development of the SMILE Pro equipment industry is being slowed by a convergence of factors: high financial barriers for clinics, limited competition among manufacturers, lengthy regulatory approval processes, surgical learning curves, weak patient awareness, narrow treatment indications, reliance on proprietary platforms, and competition from alternative technologies. Overcoming these obstacles will require coordinated efforts by manufacturers, regulators, surgeons, and healthcare providers. Cost reduction, expanded clinical indications, global training programs, and stronger patient education campaigns will be essential to accelerate the growth of SMILE Pro. Until these challenges are addressed, the industry’s expansion will remain incremental rather than exponential.
The report provides a detailed analysis of the market size, growth potential, and key trends for each segment. Through detailed analysis, industry players can identify profit opportunities, develop strategies for specific customer segments, and allocate resources effectively.
The Small Incision Lenticule Extraction Pro Equipment market is segmented as below:
By Company
ZEIS
Ziemer
Segment by Type
Myopia Treatment
Astigmatism Treatment
Myopia + Astigmatism Treatment
Segment by Application
Hospitals
Ophthalmology Clinic
Others
Each chapter of the report provides detailed information for readers to further understand the Small Incision Lenticule Extraction Pro Equipment market:
Chapter 1: Introduces the report scope of the Small Incision Lenticule Extraction Pro Equipment report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. (2020-2031)
Chapter 2: Detailed analysis of Small Incision Lenticule Extraction Pro Equipment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. (2020-2025)
Chapter 3: Provides the analysis of various Small Incision Lenticule Extraction Pro Equipment market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. (2020-2031)
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.(2020-2031)
Chapter 5: Sales, revenue of Small Incision Lenticule Extraction Pro Equipment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world..(2020-2031)
Chapter 6: Sales, revenue of Small Incision Lenticule Extraction Pro Equipment in country level. It provides sigmate data by Type, and by Application for each country/region.(2020-2031)
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. (2020-2025)
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Benefits of purchasing QYResearch report:
Competitive Analysis: QYResearch provides in-depth Small Incision Lenticule Extraction Pro Equipment competitive analysis, including information on key company profiles, new entrants, acquisitions, mergers, large market shear, opportunities, and challenges. These analyses provide clients with a comprehensive understanding of market conditions and competitive dynamics, enabling them to develop effective market strategies and maintain their competitive edge.
Industry Analysis: QYResearch provides Small Incision Lenticule Extraction Pro Equipment comprehensive industry data and trend analysis, including raw material analysis, market application analysis, product type analysis, market demand analysis, market supply analysis, downstream market analysis, and supply chain analysis.
and trend analysis. These analyses help clients understand the direction of industry development and make informed business decisions.
Market Size: QYResearch provides Small Incision Lenticule Extraction Pro Equipment market size analysis, including capacity, production, sales, production value, price, cost, and profit analysis. This data helps clients understand market size and development potential, and is an important reference for business development.
Other relevant reports of QYResearch:
Global Small Incision Lenticule Extraction Pro Equipment Market Research Report 2025
Global Small Incision Lenticule Extraction Pro Equipment Market Outlook, In‑Depth Analysis & Forecast to 2031
Global Small Incision Lenticule Extraction Pro Equipment Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedicated research team, we are well placed to provide useful information and data for your business, and we have established offices in 7 countries (include United States, Germany, Switzerland, Japan, Korea, China and India) and business partners in over 30 countries. We have provided industrial information services to more than 60,000 companies in over the world.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
Email: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
